Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New purpose of pharmaceutical composition containing pioglitazone and heparin or low molecular heparin

A technology of low molecular weight heparin and pioglitazone hydrochloride, applied in the field of medicine, to achieve the effect of reducing fat deposition

Active Publication Date: 2010-11-17
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

All in all, there is currently no very effective drug for the treatment of fatty liver in clinical practice. Therefore, finding effective intervention drugs has very important theoretical significance and application value

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New purpose of pharmaceutical composition containing pioglitazone and heparin or low molecular heparin
  • New purpose of pharmaceutical composition containing pioglitazone and heparin or low molecular heparin
  • New purpose of pharmaceutical composition containing pioglitazone and heparin or low molecular heparin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] The treatment of embodiment 1 pioglitazone and low molecular weight heparin to non-alcoholic fatty liver

[0019] 1 Preparation of non-alcoholic fatty liver model

[0020] SD rats, male, weighing 220±20g, were modeled by intragastric administration of high-fat emulsion combined with intraperitoneal injection of tetracycline. Except for the normal control group, the other groups received intraperitoneal injection of tetracycline 150 mg / kg on the first day of modeling, and then intraperitoneal injection of tetracycline 110 mg / kg once every 6 days, a total of 6 times. Except for the normal group, each group was fed with high-fat emulsion at 9:30 am every day, with a dose of 10ml·kg -1 d -1 . High-fat emulsion formula: 20g lard, 10g cholesterol, 5g fructose, 5g sucrose, 1g bile salt, 1g sodium glutamate, 15ml propylene glycol, a little soil temperature 80, distilled water to 100ml. Gastrointestinal administration of high-fat milk continued for 8W.

[0021] 2 Grouping a...

Embodiment 2

[0055] The treatment of embodiment 2 pioglitazone and heparin to non-alcoholic fatty liver

[0056] 1 Preparation of non-alcoholic fatty liver model

[0057] With embodiment 1.

[0058] 2 Grouping and administration

[0059] After one week of adaptive feeding, the model rats were randomly divided into normal group, model group and drug treatment group. The specific grouping information is shown in the table below, with 10 rats in each group. Every day at 14:30 in the afternoon, the medicine was administered into the stomach, and the dosage was as follows:

[0060] Normal control group: the same volume of sodium carboxymethylcellulose;

[0061] Model control group: the same volume of sodium carboxymethyl cellulose;

[0062] Pioglitazone group: 1.5mg / (kg.d) pioglitazone hydrochloride;

[0063] Heparin group: 6mg / (kg.d) heparin sodium;

[0064] Compound group: 1.5mg / (kg.d) pioglitazone+6mg / (kg.d) heparin sodium;

[0065] 3 detection indicators

[0066] After the last admi...

Embodiment 3

[0089] The preparation of embodiment 3 compound capsules

[0090] Calcium Heparin 2g

[0091] Pioglitazone Hydrochloride 20g

[0092] 180g pregelatinized starch

[0093] Mannitol 160g

[0094] Lactose 80g

[0095] 6% PVP in 95% ethanol solution

[0096] Micronized silica gel 4.5g

[0097] Preparation process: pass the heparin calcium, pioglitazone hydrochloride, pregelatinized starch, mannitol, lactose and micropowder silica gel in the prescription through a 100-mesh sieve, mix well, add 6% PVP in 95% ethanol solution to granulate, and bake at 60°C Dry, sieve through a 18-mesh sieve, and fill the capsules.

[0098] The heparin calcium in this embodiment can also be replaced by low molecular weight heparin calcium or low molecular weight heparin sodium.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the application of pioglitazone and heparin or low molecular heparin or pharmaceutically acceptable salts thereof or derivatives thereof to preparing a pharmaceutical composition, in particular to the application to preparing a medicament for preventing or treating fatty liver. the purpose of the pioglitazone and the heparin or the low molecular heparin or the pharmaceutically acceptable salts thereof in lessening fat deposition in rat hepatocytes and the synergy of a pioglitazone and heparin or low molecular heparin compound in preventing or treating the rat fatty liver are proved by animal tests. The invention provides a new candidate medicament for searching a medicament for lessening fat deposition in hepatocytes and treating diseases caused by clinic lipid metabolism, such as fatty liver, and the like and therefore enriches the prior art.

Description

technical field [0001] The invention belongs to the field of medicine, and specifically relates to the application of pioglitazone and heparin or low-molecular-weight heparin or its pharmaceutically acceptable salt or their derivatives in the preparation of a pharmaceutical composition, especially in the preparation of a method for preventing or treating fatty liver application in medicines. Background technique [0002] Fatty liver refers to the pathological changes caused by excessive accumulation of fat in liver cells due to various reasons. Fatty liver disease is a serious threat to the health of Chinese people, becoming the second largest liver disease after viral hepatitis, and has been recognized as a common cause of hidden cirrhosis. Fatty liver is a common clinical phenomenon rather than an independent disease. Its clinical manifestations are asymptomatic in mild cases, and violent in severe cases. Generally speaking, fatty liver is a reversible disease, early di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/727A61K31/4439A61P1/16
Inventor 赵志全陈凯
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com